Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 5, 2004. The report serves as a notification of changes in director interests in the company's Ordinary Shares and American Depositary Receipts (ADRs) rather than a comprehensive financial performance report.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transactions:
- Share Price (ADRs): $43.650 and $40.98 per ADR.
- Share Price (Ordinary Shares): £11.08 per Ordinary Share.
- Dividend Date: September 30, 2004.
Material Changes
The filing details increases in shareholdings for several directors resulting from the re-investment of dividends paid on September 30, 2004. These changes include:
- Dr. J.P. Garnier: Increased interest by 295.235 ADRs (Performance Share Plan) and 1,356.151 ADRs (Mid-Term Incentive Plan) at $43.650 per ADR. Additionally, a notional increase of 1,822.957 ADRs at $40.98 per ADR was recorded.
- Dr. T. Yamada: Notional increase of 546.887 ADRs at $40.98 per ADR.
- Mr. J.D. Coombe: Notional increase of 1,105.739 Ordinary Shares at £11.08 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It notes that notional dividends accrued under the Performance Share Plan will be paid out in proportion to the percentage of holdings that vest following the end of the relevant three-year measurement period.
Investor Verification Checklist
- Verify the total aggregate shareholding of Dr. J.P. Garnier, Dr. T. Yamada, and Mr. J.D. Coombe following these transactions.
- Confirm the vesting schedule and conditions for the Performance Share Plan and Mid-Term Incentive Plan mentioned.
- Review the full annual report (Form 20-F) for comprehensive financial metrics, as this filing is limited to director interest disclosures.